Skip to content
MS
Sign in
Single-pathway Pathway metabolite unreviewed

Glycogen limit dextrin

0
Pathways
0
Categories
0
As substrate
0
As product
What can this become? Show on map

Reactions involving Glycogen limit dextrin

Every recorded step where this molecule takes part

All 1 Consumed 1 Produced 0

Showing all 1 reactions.

Recent literature

Refresh

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Enhanced lysosomal glycogen breakdown is associated with liver tumorigenesis in glycogen storage disease type III.

    Montalvo-Romeral V, Jauze L, Perrot G, Amaouche M, Gardin A, Aguilar González A, Leblond A, Zitoun-Ardon C, E… · 2025-12-02

    open access unreviewed
  2. 2
    Hepatic glycogen storage disease: Deciphering the genotype-phenotype conundrum.

    Samanta A, Ray G. · 2025-09-09

    open access unreviewed
  3. 3
    Long-Term Correction of Murine Glycogen Storage Disease Type III by AAV-Mediated Gene Therapy Using an Immunotolerizing Dual Promoter to Express Bacterial Pullulanase.

    Liao KA, Lim JA, Choi SJ, Yi H, Sun B. · 2025-04-17

    open access unreviewed
  4. 4
    Galectin-3: a novel biomarker of glycogen storage disease type III.

    Rossiaud L, Miagoux Q, Benabides M, Reiss O, Jauze L, Jarrige M, Polvèche H, Malfatti E, Laforêt P, Ronzitti … · 2025-04-14

    cited 1× open access unreviewed
  5. 5
    Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.

    Maiorana A, Tagliaferri F, Dionisi-Vici C. · 2023-04-21

    cited 17× open access unreviewed
  6. 6
    Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice.

    Lim JA, Kishnani PS, Sun B. · 2022-12-08

    cited 12× open access unreviewed
  7. 7
    Improvement in hypertrophic cardiomyopathy after using a high-fat, high-protein and low-carbohydrate diet in a non-adherent child with glycogen storage disease type IIIa.

    Kumru Akin B, Ozturk Hismi B, Daly A. · 2022-08-01

    cited 8× open access unreviewed
  8. 8
    Diurnal variability of glucose tetrasaccharide (Glc<sub>4</sub>) excretion in patients with glycogen storage disease type III.

    Young SP, Khan A, Stefanescu E, Seifts AM, Hijazi G, Austin S, Kishnani PS. · 2020-11-03

    cited 12× open access unreviewed
  9. 9
    Involvement of glycogen debranching enzyme in bladder cancer.

    Weinhaus B, Guin S. · 2017-05-09

    cited 4× unreviewed
  10. 10
    Hyperlipidemia in glycogen storage disease type III: effect of age and metabolic control.

    Bernier AV, Sentner CP, Correia CE, Theriaque DW, Shuster JJ, Smit GP, Weinstein DA. · 2008-08-19

    cited 19× unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.